Abstract
Interleukin-33 that binds to the membrane receptor ST2L, can not only regulate mast cells, eosinophils, and group 2 innate lymphoid cells（ILC2s）, but also affect the function of regulatory T cells（Treg） and Follicular helper T cells（Tfh）. Interleukin-33 can activate the NF-κB and MAPK signaling pathways of the above cells, then participates in allergic immunity reaction. IL-33/ST2 signaling pathway is closely related to the allergic rhinitis（AR）. IL-33 has been used as a new biomarker to evaluate the effect of AR treatment. At the same time, antagonizing IL-33 is also expected to become a new treatment. This article reviewed the latest research of IL-33/ST2 signaling pathway in the field of AR.